Used in Lieu of PTO/SB/08A/B
(Based on PTO 04-07 version)

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 1

Complete If Known	
Application Number	10/767,018
Filing Date	January 29, 2004
First Named Inventor	Brent R. Stockwell
Art Unit	1643
Examiner Name	K. A. Canella
Attorney Docket Number	WIBL-P01-011

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number: Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
/KAC/	AA	US-6,831,085	12-14-2004	Bergnes et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document: Country Code[3]-Number[4]-Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T[6]
/KAC/	BA	JP-07-258224-A	10-09-1995	Dai Ichi Seiyaku Co. Ltd (abstract)		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1]Applicant's unique citation designation number (optional). [2]Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Karen A. Canella, Ph.D./	Date Considered	11/26/2007

Used in Lieu of PTO/SB/08A/B
(Based on PTO 04-07 version)

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 2

Complete If Known	
Application Number	10/767,018
Filing Date	January 29, 2004
First Named Inventor	Brent R. Stockwell
Art Unit	1643
Examiner Name	K. A. Canella
Attorney Docket Number	WIBL-P01-011

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
/KAC/	AB	US-20040248221-A1	12-09-2004	Stockwell	
/KAC/	AC	US-20030171316-A1	09-11-2003	Jupe	
/KAC/	AD	US-20040096444-A1	05-20-2004	Pizzo et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3]-Number[4]-Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T[6]
/KAC/	BB	WO-02/099122	12-12-2002	Exelixis Inc et al.		
/KAC/	BC	WO-2004/030615	04-15-2004	Genentech Inc et al.		
/KAC/	BD	WO-04/055519	07-01-2004	Hoffmann La Roche et al.		
/KAC/	BE	WO-99/21988	05-06-1999	Shanghai Second Medical Univer et al.		
/KAC/	BF	WO-02/083143	10-24-2002	Tularik Inc et al.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
/KAC/	CR2	ABDEL-ALIM, et al., "Synthesis and biological activities of 6-bromo-2,3-disubstituted-4-(3H)-quinazolinones," Indian Journal of Chemistry, 33(B):260-265 (1994).	
/KAC/	CS2	ADAM, et al., "Comprehensive Proteomic Analysis of Breast Cancer Cell Membranes Reveals Unique Proteins with Potential Roles in Clinical Cancer," JBC Papers in Press, 1-60 (2002).	
/KAC/	CT2	AGER, et al., "Synthesis and Central Nervous System Activity of Quinazolones Related to 2-Methyl-3-(o-tolyl)-4(3H)-quinazolone (Methaqualone)," J. Med. Chem., 20(3):379-386 (1977).	
/KAC/	CU2	Database Registry Chemical Abstracts Service, Columbus, Ohio, US; (2001-05-21), XP002405284, RN 336853-04-4.	
/KAC/	CV2	Database Registry Chemical Abstracts Service, Columbus, Ohio, US; (2001-05-21), XP002405285, RN 336813-90-2.	
/KAC/	CW2	DOLMA, et al., "Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells," Cancer Cell, 3:285-296 (2003).	
/KAC/	CX2	FIGYS, et al., "VDAC Can Control Apoptosis By Controlling Metabolism," Biophysical Jr., 86(1):463A-464A (2004).	
/KAC/	CY2	GUPTA, et al., "A Novel Class of Hypoglycaemic Agents: Syntheses & SAR in 2-Substituted 4(3H)-Quinazolones, 2-Substituted 4-Hydroxypolymethylene[5,6]pyrimidines & 3-Substituted 4-Oxo-pyrido[1,2-α]pyrimidines," Indian Journal of Chemistry, 9:201-206 (1971).	
/KAC/	CZ2	IKONEN, et al., "Prohibitin, an antiproliferative protein, is localized to mitochondria," FEBS Letters, 358(3):273-277 (1995).	
/KAC/	CA3	KOZHEVNIKOV, et al., "Synthesis in the 2-aminoethyl-3-(2'-tolyl)-4-quinazolone," Khimiko-	

Examiner Signature		Date Considered	

Used in Lieu of PTO/SB/08A/B
(Based on PTO 04-07 version)

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	2	of	2

Complete if Known	
Application Number	10/767,018
Filing Date	January 29, 2004
First Named Inventor	Brent R. Stockwell
Art Unit	1643
Examiner Name	K. A. Canella
Attorney Docket Number	WIBL-P01-011

		Farmatsevticheskii Zhurnal, 4(11):22-25 (1970).	
/KAC/	CB3	TANI, et al., "Studies on Biologically Active Halogenated Compounds II. Chemical Modifications of 6-amino-2-fluoromethyl-3-(o-toly)-4(3H) quinazolinone and the CNS depressant activities of related compounds," Chemical and Pharmaceutical Bulletin, Pharmaceutical Society of Japan, 27(11):2675-2687 (1979).	
/KAC/	CC3	VERMA, et al., "A New Potent Anti-Inflammatory Quinazolone," Pharmacological Research Communications, Italian Pharmacological Society, IT, 13(10):967-979 (1981).	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1]Applicant's unique citation designation number (optional). [2]Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Karen A. Canella, Ph.D./	Date Considered	11/26/2007

PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 2 of 4

Complete If Known	
Application Number	10/767018
Filing Date	January 29, 2004
First Named Inventor	Brent R. Stockwell
Art Unit	1642
Examiner Name	Not Yet Assigned
Attorney Docket Number	WIBL-P01-011

KAC		chemical screening in engineered human tumor cells," Cancer Cell, 3:285-296 (2003).	
KAC	CN	Druker, B.J. et al., "Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells", Nature Medicine, 2:561-566 (1996) (Abstract)	
	CO	Elenbaas, B. et al., "Human breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells", Genes & Development, 15:50-65 (2001)	
	CP	Eng, W-K., *et al.*, "Evidence that DNA Topoisomerase I Is Necessary for the Cytotoxic Effects of Camptothecin," *Mol Pharmacol*, 34:755-60 (1988).	
	CQ	Hahn, W. C. and Weinberg, R. A., "Modelling the Molecular Circuitry of Cancer", Nature Reviews Cancer, 2:331-341 (2002)	
	CR	Hahn, W.C., *et al.*, "Creation of human tumour cells with defined genetic elements," Nature, 400:464-468 (1999).	
	CS	Hahn, W.C., *et al.*, "Enumeration of the Simian Virus 40 Early Region Elements Necessary for Human Cell Transformation," *Mol Cell Biol*, 22(7):2111-23 (2002).	
	CT	Hahn, W.C., *et al.*, "Inhibition of telomerase limits the growth of human cancer cells," Nat Med, 5(10):1164-1170 (1999).	
	CU	Hamad, N. M. et al., "Distinct requirements for Ras oncogenesis in human versus mouse cells", Genes & Development, 16:2045-2057 (2002)	
	CV	Harley, C.B., "Telomerases," *Pathol Biol (Paris)*, 42:342-5 (1994).	
	CW	Hsiang, Y-H. and Liu, L.F., "Identification of Mammalian DNA Topoisomerase I as an Intracellular Target of the Anticancer Drug Camptothecin," *Cancer Res*, 48:1722-6 (1988).	
	CX	Hsiang, Y-H., *et al.*, "Arrest of Replication Forks by Drug-stabilized Topoisomerase I-DNA Cleavable Complexes as a Mechanism of Cell Killing by Camptothecin," *Cancer Res*, 49:5077-82 (1989).	
	CY	Jorcyk, C.L., *et al.*, "Development and Characterization of a Mouse Prostate Adenocarcinoma Cell Line: Ductal Formation Determined by Extracellular Matrix," The Prostate, 34:10-22 (1998).	
	CZ	Kohno, T., *et al.*., "Alterations of the *PPP1R3* Gene in Human Cancer," *Cancer Res*, 59:4170-4 (1999).	
	CA1	Laurent, G. and Jaffrezou, J-P., "Signaling pathways activated by daunorubicin," Blood, 98(4):913-924 (2001).	
	CB1	Lessnick, S.L., *et al.*, "The Ewing's sarcoma oncoprotein EWS/FLI induces a p53- dependent growth arrest in primary human fibroblasts," Cancer Cell, 1:393-401 (2002).	
	CC1	Liu, L.F., *et al.*, "Mechanism of Action of Camptothecin," Annals N Y Acad Sci, 922:1-10 (2000).	
	CD1	Loomis, C.R. and Bell, R.M., "Sangivamycin, a Nucleoside Analogue, Is a Potent Inhibitor of Protein Kinase C*," J Biol Chem, 263(4):1682-1692 (1998).	
	CE1	Madden, K.R., and Champoux, J.J., "Overexpression of Human Topoisomerase I in Baby Hamster Kidney Cells: Hypersensitivity of Clonal Isolates to Camptothecin," *Cancer Res*, 52:525-32 (1992).	
	CF1	Majno, G. and Joris, I., "Apoptosis, Oncosis, and Necrosis," *Am J Pathol*, 146(1):3-15 (1995).	
	CG1	Makin, G., "Targeting apoptosis in cancer chemotherapy," *Expert Opin Ther Targets*, 6(1):73-84 (2002).	
	CH1	Miller, M.L. and Ojima, I., "Chemistry and Chemical Biology of Taxane Anticancer Agents," Chem. Record, 1:195-211 (2001).	
	CI1	Millward, T.A., *et al.*, "Regulation of protein kinase cascades by protein phosphatase 2A," Trends Biochem Sci, 24:186-91 (1999).	
	CJ1	Mokbel, K. and Hassanally, D., "From HER2 to Herceptin," *Curr Med Res Opin*, 17(1):51-9 (2001).	
	CK1	Möller, I., *et al.*, "Anthracycline-derived chemotherapeutics in apoptosis and free radical	

Examiner Signature	/Karen A. Canella, Ph.D./	Date Considered	02/20/2007

PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 3 of 4

Complete If Known	
Application Number	10/767018
Filing Date	January 29, 2004
First Named Inventor	Brent R. Stockwell
Art Unit	1642
Examiner Name	Not Yet Assigned
Attorney Docket Number	WIBL-P01-011

KAC		cytotoxicity (Review), *Int J Mol Med*, 1:491-4 (1998).	
KAC	CL1	Nociari, M.M., *et al.*, "A novel one-step, highly sensitive fluorometric assay to evaluate cell-mediated cytotoxicity," *J. Immunol. Methods*, 213:157-167 (1998).	
	CM1	Pallas, D.C., *et al*, "Polyoma small and middle T antigens and SV40 small t antigen form stable complexes with protein phosphatase 2A," Cell, 60:167-176 (1990)	
	CN1	Perez-Stable, C., *et al.*, "Prostate Cancer Progression, Metastasis, and Gene Expression in Transgenic Mice," *Cancer Res*, 57:900-6 (1997).	
	CO1	Rao, K.V., "Structure of Sangivamycin," *J Med Chem*, 11:939-41 (1968).	
	CP1	Rich, J.N., *et al.*, "A Genetically Tractable Model of Human Glioma Formation," *Cancer Res*, 61:3556-60 (2001).	
	CQ1	Richard, D., *et al.*, "Free radical production and labile iron pool decrease triggered by subtoxic concentration of aclarubicin in human leukemia cell lines," Leukemia Res, 26:927-931 (2002).	
	CR1	Ruediger, R., *et al.*, "Alterations in protein phosphatase 2A subunit interaction in human carcinomas of the lung and colon with mutations in the Aβ subunit gene," Oncogene, 20:1892-1899 (2001).	
	CS1	Ruediger, R., *et al.*, "Disruption of protein phosphatase 2A subunit interaction in human cancers with mutations in the Aα subunit gene," Oncogene, 20:10-15 (2001).	
	CT1	Sabatini, D.M., *et al.*, "RAFT1: A mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs," Cell, 78:35-43 (1994)	
	CU1	Sandmoller, A., *et al.*, "A Transgenic Mouse Model for Lung Adenocarcinoma," *Cell Growth & Differ*, 6:97-103 (1995).	
	CV1	Schreiber, S.L., "Chemical Genetics Resulting from a Passion for Synthetic Organic Chemistry, Bioorg. Med. Chem., 6:1127-1152 (1998).	
	CW1	Sellers, W.R. and Kaelin, W.G., "Role of the retinoblastoma protein in the pathogenesis of human cancer," J Clin Oncol, 15:3301-3312 (1997).	
	CX1	Shawver, L.K., *et al.*, "Smart drugs: Tyrosine kinase inhibitors in cancer therapy," Cancer Cell, 1:117-123 (2002).	
	CY1	Sherr, C.J., "The *INK4a*/ARF Network in Tumour Suppression," Nat Rev Mol Cell Biol, 2:731-737 (2001).	
	CZ1	Shi, Y., *et al.*, "Enhanced Sensitivity of Multiple Myeloma Cells Containing *PTEN* Mutations to CCI-779," *Cancer Res*, 62:5027-34 (2002).	
	CA2	Simons, A., *et al.*, "Establishment of a Chemical Synthetic Lethality Screen in Cultured Human Cells," Genome Res, 11:266-273 (2001).	
	CB2	Stockwell, B. R., "Chemical Genetic Screening Approaches to Neurobiology," Neuron, 36:559-562 (2002).	
	CC2	Stockwell, B. R., "Frontiers in chemical genetics", Trends Biotechnol 18, 449-55, (2000)	
	CD2	Stockwell, B.R., "Chemical Genetics: Ligand-Based Discovery of Gene Function, Nat Rev Genet, 1:116-125 (2000).	
	CE2	Stockwell, B.R., "The biological magic behind the bullets," Nature Biotechnology, 22(1):37-38 (2004).	
	CF2	Stockwell, B.R., *et al.*, "High-throughput screening of small molecules in miniaturized mammalian cell-based assays involving post-translational modifications," Chem Biol, 6:71-83 (1999).	
	CG2	Testa, J.R. and Giordano, A., "SV40 and cell cycle perturbations in malignant mesothelioma," Seminars in Cancer Biol, 11:31-8 (2001).	
	CH2	Torrance, C.J., *et al.*, "Use of isogenic human cancer cells for high-throughput screening and drug discovery," Nat Biotechnol, 19:940-945 (2001).	
	CI2	Traganos, F., *et al.*, "Induction of Apoptosis by Camptothecin and Topotecan," *Ann N Y Acad Sci*, 803:101-10 (1996).	
	CJ2	Tsao, Y-P., *et al.*, "Interaction between Replication Forks and Topoisomerase I-DNA	

Examiner Signature	KAC /Karen A. Canella, Ph.D./	Date Considered	02/20/2007

9736288_1